<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01836341</url>
  </required_header>
  <id_info>
    <org_study_id>12-279</org_study_id>
    <nct_id>NCT01836341</nct_id>
  </id_info>
  <brief_title>Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation</brief_title>
  <official_title>A Dose-Finding Study Of Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Comprehensive Cancer Network</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <brief_summary>
    <textblock>
      The purpose of this Phase I study is to test the safety of combining afatinib with standard
      chemotherapy and radiation. The drug afatinib will be given before the chemotherapy and
      radiation therapy to shrink the tumor and evaluate how afatinib affects the patient. This
      study will then test the safety of afatinib at different dose levels when combined with the
      chemotherapy drugs cisplatin or carboplatin, and pemetrexed. These treatments will be given
      during radiation treatment and the drug afatinib will be continued after chemotherapy and
      radiation.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>maximum tolerated dose</measure>
    <time_frame>1 year</time_frame>
    <description>This will be defined as the dose at which fewer than 1:6 patients experiences a dose-limiting toxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>local control rate</measure>
    <time_frame>at 1 year and at 2 years</time_frame>
    <description>will be determined as the proportion of patients who start the concurrent phase who are alive and free of local failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tolerability of adjuvant afatinib</measure>
    <time_frame>at 3 months</time_frame>
    <description>Tolerability will be defined by in terms of dose reductions, delays and discontinuations of patients who have not had disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median progression free survival</measure>
    <time_frame>2 years</time_frame>
    <description>PFS is defined as the duration of time from start of treatment to time of progression of disease or death, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>median overall survival</measure>
    <time_frame>2 years</time_frame>
    <description>will be calculated using Kaplan-Meier estimates among all patients enrolled.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Afatinib w Cisplatin Pemetrexed Chemoradiation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>induction afatinib 40mg daily x 28days Cisplatin or Carboplatin (can be used if patient is not eligible for cisplatin) + Pemetrexed + 50Gy to pretreatment field boost to 60Gy to residual tumor + afatinib dose escalation*
*afatinib dose levels: 20mg daily, 30mg daily &amp; 40mg daily (3+3 design) Then adjuvant afatinib x 2 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <arm_group_label>Afatinib w Cisplatin Pemetrexed Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Afatinib w Cisplatin Pemetrexed Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <arm_group_label>Afatinib w Cisplatin Pemetrexed Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pemetrexed</intervention_name>
    <arm_group_label>Afatinib w Cisplatin Pemetrexed Chemoradiation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation therapy</intervention_name>
    <arm_group_label>Afatinib w Cisplatin Pemetrexed Chemoradiation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Unresectable or inoperable, stage III or locoregional recurrence without evidence of
             distant, metastatic disease

          -  Pathologic confirmation of NSCLC at MSKCC

          -  Documentation of a sensitizing EGFR mutation

          -  Age ≥ 18 years

          -  No contraindication to definitive thoracic radiation therapy with concurrent
             chemotherapy

        Adequate organ function as defined by:

          -  Calculated creatinine clearance≥ 45 mL/min (by Cockcroft-Gault)

          -  Total bilirubin less than 1.5 x ULN (unless known Gilbert's disease) and AST/ALT less
             than 3 x ULN

          -  Absolute neutrophil count greater than 1500/mm3

          -  Platelet count greater than 100,000/mm3

          -  Women of childbearing age must have a negative blood pregnancy test

          -  Men and women of childbearing potential must be willing to use effective contraception
             while on treatment and for at least 3 months there after

        Exclusion Criteria:

          -  Prior chemotherapy or radiation therapy for this lung cancer (history of prior lung
             cancer that has been treated and deeded inactive by the clinician is acceptable)

          -  Ineligible for cisplatin or carboplatin per medical oncologist

          -  Ineligible for pemetrexed per medical oncologist

          -  Greater than minimal, exudative, or malignant pleural effusion

          -  Calculated creatinine clearance by Cockcroft &amp; Gault method ≤45 ml/min

          -  Unstable congestive heart failure

          -  Ejection fraction &lt;50% as assessed by MUGA or echocardiogram

          -  Interstitial lung disease

          -  Patient requiring on-going treatment with a potent inhibitor (cyclosporin,
             erythromycin, ketoconazole, itraconazole, quinidine, phenobarbital with quinidine,
             ritonavir, valspodar, verapamil) or inducer of P-gp (St. John's wort or rifampin)

          -  Women who are breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jamie E. Chaft, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <link>
    <url>http://www.mskcc.org/</url>
    <description>Memorial Sloan-Kettering Cancer Center</description>
  </link>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 17, 2013</study_first_submitted>
  <study_first_submitted_qc>April 17, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2013</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Afatinib</keyword>
  <keyword>Cisplatin</keyword>
  <keyword>Carboplatin</keyword>
  <keyword>Pemetrexed</keyword>
  <keyword>Radiation therapy</keyword>
  <keyword>EGFR mutation</keyword>
  <keyword>12-279</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

